IDHIFA ® is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not …

2024年6月24日 · Idhifa is used to treat acute myeloid leukemia in adults with an IDH2 mutation. Idhifa is used when AML has come back or has not improved with prior treatment. Idhifa can …

Enasidenib, sold under the brand name Idhifa, is an anti-cancer medication used to treat relapsed or refractory acute myeloid leukemia. [2] [3] It is an inhibitor of isocitrate dehydrogenase 2 …

IDHIFA是适用为当被一种FDA-批准的测试检测到有一个异柠檬酸脱氢酶-2 (IDH2)突变有复发或难治性急性髓性白血病 (AML)成年患者的治疗。 为AML用IDHIF的治疗选择患者根据在血或骨髓 …

IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 …

恩西地平 （Enasidenib，Idhifa）是一种针对 异柠檬酸脱氢酶2 （IDH2）的抑制剂，由Agios和Celgene合作开发。 该药物于2017年8月1日获得了美国食品药品管理局（FDA）的批准上 …

Discover IDHIFA® (enasidenib), an IDH2 inhibitor for relapsed/refractory acute myeloid leukemia (AML) with an IDH2 mutation. See Safety Information and Boxed WARNING on differentiation …

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific …

2025年1月16日 · 1.1 Acute Myeloid Leukemia - IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate …

IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with...